Buckle Up, Toot Toot the Chart linked, page-9

I believe these short-term movements have little to do with the core of the business. Of course it will trade up and down, in the coming months. If the share price receives a bolstering then I'm sure it would be thanks to those who arise from a financial or other backround, rather than those from a healthcare and/or pharmaceutical background. I think it would be foolish to buy in now and even worse so to do at higher levels or for the long-term. In terms of this injectable formulation doing better than the nsaids or intra-articular steroidal injections uh... that's still unproven. I wouldn't bank on it. I certainly wouldn't bank on there being a substantially improved outcome compared with traditional treatments.